Effects of the Selective Mineralocorticoid Receptor Antagonist Eplerenone on Extracellular Adenosine Formation in Humans in Vivo.

Trial Profile

Effects of the Selective Mineralocorticoid Receptor Antagonist Eplerenone on Extracellular Adenosine Formation in Humans in Vivo.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jan 2014

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Heart failure; Hypertension
  • Focus Pharmacodynamics
  • Acronyms eplerenone-01
  • Most Recent Events

    • 30 Jan 2014 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 31 Oct 2013 Planned End Date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 19 Apr 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01837108)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top